OurPharma Holdings operates a 503B outsourcing facility that produces high-quality compounded pharmaceuticals, including sterile injectables and intravenous fluids, to address critical medication shortages in healthcare. The company ensures product reliability through independent testing and extensive stability data, enhancing patient care and safety.
Funding
$17M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Healthcare providers often face critical medication shortages, impacting patient care and requiring them to seek alternative supply sources. Ensuring the quality and reliability of compounded pharmaceuticals during these shortages is paramount for patient safety.
Solution
OurPharma Holdings operates as a 503B outsourcing facility, specializing in the production of high-quality compounded pharmaceuticals, including sterile injectables, intravenous fluids, and medication cassettes, to address critical medication shortages. The company focuses on sterile-to-sterile and API-sterile compounding, adhering to current Good Manufacturing Practices (cGMP) and maintaining FDA registration. All products undergo testing by an independent, FDA-regulated analytics lab, with expiration dating backed by extensive stability data. OurPharma aims to provide healthcare organizations with a reliable source of critically needed medications, ensuring transparency across all stages of the manufacturing process.
Target Audience
OurPharma serves hospitals, health systems, and outpatient clinics that require a reliable supply of high-quality compounded sterile pharmaceuticals to overcome medication shortages and ensure patient care.
Features
- Portfolio of ready-to-administer sterile injectables, intravenous fluids, and medication cassettes
- Expertise in sterile pharmaceutical manufacturing and repackaging
- Products tested by an independent, FDA-regulated analytics lab
- Extensive internal drug diversion program
- Expiration dating backed by extended stability data
- Ongoing product development supporting dynamic provider and patient needs
- Transparency across all stages of the manufacturing process
- Adherence to current Good Manufacturing Practices (cGMP)